2020
Liver Pathologic Changes After Direct-Acting Antiviral Agent Therapy and Sustained Virologic Response in the Setting of Chronic Hepatitis C Virus Infection.
Celli R, Saffo S, Kamili S, Wiese N, Hayden T, Taddei T, Jain D. Liver Pathologic Changes After Direct-Acting Antiviral Agent Therapy and Sustained Virologic Response in the Setting of Chronic Hepatitis C Virus Infection. Archives Of Pathology & Laboratory Medicine 2020, 145: 419-427. PMID: 32810870, PMCID: PMC10960369, DOI: 10.5858/arpa.2020-0008-oa.Peer-Reviewed Original ResearchConceptsHepatocellular carcinomaHCC developmentChronic hepatitis C virus (HCV) infectionChronic viral hepatitis C infectionHepatitis C virus infectionViral hepatitis C infectionTissue polymerase chain reactionAntiviral agent therapyLiver histologic findingsLiver pathologic changesNon-SVR groupOccult HCV infectionPersistent liver inflammationSuccessful DAA therapyC virus infectionHepatitis C infectionSubset of patientsDegree of inflammationNumber of patientsPresence of virusDAA therapySVR patientsVirologic responseC infectionHCV infection
2019
Macrotrabecular Hepatocellular Carcinoma
Jeon Y, Benedict M, Taddei T, Jain D, Zhang X. Macrotrabecular Hepatocellular Carcinoma. The American Journal Of Surgical Pathology 2019, 43: 943-948. PMID: 31135484, DOI: 10.1097/pas.0000000000001289.Peer-Reviewed Original ResearchMeSH KeywordsAgedAlpha-FetoproteinsCarcinoma, HepatocellularDisease ProgressionFemaleHepatectomyHepatitis BHepatitis CHumansLiver CirrhosisLiver NeoplasmsLiver TransplantationMaleMiddle AgedNeoplasm GradingNeoplasm Recurrence, LocalNeoplasm StagingProgression-Free SurvivalRetrospective StudiesRisk FactorsTime FactorsTumor BurdenConceptsHepatocellular carcinomaHCC subtypesHigh alpha-fetoprotein levelsWorse recurrence-free survivalDistinct HCC subtypeHepatitis C infectionRecurrence-free survivalAlpha-fetoprotein levelsAnaplastic tumor cellsHigh histologic gradePoor overall survivalConventional hepatocellular carcinomaHigh recurrence rateHigher AJCC stageDetailed pathologic evaluationMacrotrabecular patternC infectionPrimary resectionHepatitis BOverall survivalPathologic evaluationAJCC stageClinicopathologic featuresHistologic subtypeRecurrence rate
2015
A Nodular Foreign Body Reaction in a Dialysis Patient Receiving Long-term Treatment With Lanthanum Carbonate
Valika AK, Jain D, Jaffe PE, Moeckel G, Brewster UC. A Nodular Foreign Body Reaction in a Dialysis Patient Receiving Long-term Treatment With Lanthanum Carbonate. American Journal Of Kidney Diseases 2015, 67: 128-132. PMID: 26385816, DOI: 10.1053/j.ajkd.2015.07.033.Peer-Reviewed Case Reports and Technical NotesConceptsEnd-stage renal diseaseLanthanum carbonate treatmentUpper gastrointestinal bleedSimilar pathologic findingsLong-term treatmentCollections of histiocytesForeign body reactionGastrointestinal bleedGastrointestinal bleedingUpper endoscopyDialysis patientsHIV infectionRenal diseaseComorbid conditionsPathologic findingsAdverse reactionsHyperechoic materialEndoscopic ultrasoundHyperplastic epitheliumPhosphate bindersGiant cellsLanthanum carbonateGranular cytoplasmic materialPatientsBody reaction
2010
Dantrolene mitigates caerulein-induced pancreatitis in vivo in mice
Orabi AI, Shah AU, Ahmad MU, Choo-Wing R, Parness J, Jain D, Bhandari V, Husain SZ. Dantrolene mitigates caerulein-induced pancreatitis in vivo in mice. AJP Gastrointestinal And Liver Physiology 2010, 299: g196-g204. PMID: 20448143, PMCID: PMC2904115, DOI: 10.1152/ajpgi.00498.2009.Peer-Reviewed Original ResearchMeSH KeywordsAmylasesAnimalsApoptosisCalcium Channel BlockersCalcium SignalingCeruletideCytoprotectionDantroleneDisease Models, AnimalEnzyme ActivationFluorescent Antibody TechniqueIn Situ Nick-End LabelingMaleMiceMice, Inbred C57BLMicroscopy, ElectronPancreasPancreatitisRyanodine Receptor Calcium Release ChannelSeverity of Illness IndexTime FactorsTrypsinConceptsPancreatic trypsin activityCaerulein-induced pancreatitisRyanodine receptorAcinar cellsMouse pancreatic sectionsHigh-risk settingsTUNEL-positive cellsLater time pointsRyR inhibitor dantroleneDantrolene pretreatmentHistological severityAcute pancreatitisPancreatic acinar cellsInflammatory disordersProphylactic treatmentRyR inhibitionSerum amylasePancreatitis inductionPancreatic sectionsPancreatitisAdequate treatmentTrypsin activityEarly markerCaerulein hyperstimulationUltrastructural derangements
2009
HCV Response in Patients With End Stage Renal Disease Treated With Combination Pegylated Interferon α-2a and Ribavirin
Hakim W, Sheikh S, Inayat I, Caldwell C, Smith D, Lorber M, Friedman A, Jain D, Bia M, Formica R, Mehal W. HCV Response in Patients With End Stage Renal Disease Treated With Combination Pegylated Interferon α-2a and Ribavirin. Journal Of Clinical Gastroenterology 2009, 43: 477-481. PMID: 19142165, PMCID: PMC3715868, DOI: 10.1097/mcg.0b013e318180803a.Peer-Reviewed Original ResearchConceptsEnd-stage renal diseaseHepatitis C virusCombination therapyRenal diseasePosttreatment rateSide effectsSerious adverse side effectsDose of ribavirinNon-ESRD patientsSafe therapeutic optionEarly virologic responseProspective observational studyMonths of treatmentStage renal diseaseCases of anemiaInitial response rateLength of treatmentInterferon α-2aAdverse side effectsPO weeklyVirologic responseESRD patientsHCV infectionESRD populationHCV response